When prostate cancer patients need therapy to reduce male hormone levels, delivering some of the treatment via a patch on the ...

Prostate-specific antigen responses were similar between transdermal estradiol and hormone therapy combined with androgen ...

Progression-free survival (PFS) in oligometastatic prostate cancer improved significantly with metastasis-directed therapy ...

Responses were similar among patients with estrogen patches and ARPIs compared to luteinizing hormone releasing hormone ...

Savita Dandapani, MD, PhD, discusses the rationale behind a study evaluating the combination of radium-223, hormone therapy, ...

A major discovery by Australian researchers of a key driver of prostate cancer could lead to the next generation of targeted ...

Quality of life, treatment impact and duration, and the importance of individualized therapy are at the center of ...

New Data for NUBEQA® Build on Safety and Efficacy Results Across Subgroups of Patients with Metastatic Hormone-Sensitive ...

Bayer is committed to advancing treatment in prostate cancer care, showcasing new analyses from its comprehensive clinical trial program for NUBEQA ® (darolutamide), which includes the ARANOTE, ...

“Prostate-specific membrane antigen (PSMA) PET imaging can identify patients suitable for PSMA-targeted radioligand therapy such as lutetium-177-PSMA-617. This is crucial for mCRPC patients who have ...